BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 216,070 shares, a drop of 13.4% from the December 31st total of 249,388 shares. Based on an average daily trading volume, of 71,577 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.5% of the shares of the company are sold short. Currently, 2.5% of the shares of the company are sold short. Based on an average daily trading volume, of 71,577 shares, the days-to-cover ratio is currently 3.0 days.

BioCardia Stock Performance

NASDAQ BCDA traded up $0.01 during trading hours on Wednesday, hitting $1.17. The company had a trading volume of 2,222 shares, compared to its average volume of 61,249. BioCardia has a 52 week low of $1.00 and a 52 week high of $3.20. The firm has a market capitalization of $12.41 million, a price-to-earnings ratio of -0.79 and a beta of 0.61. The firm has a 50 day simple moving average of $1.33 and a 200 day simple moving average of $1.54.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. On average, research analysts forecast that BioCardia will post -3.52 earnings per share for the current year.

Institutional Investors Weigh In On BioCardia

An institutional investor recently bought a new position in BioCardia stock. Cetera Investment Advisers acquired a new position in shares of BioCardia, Inc. (NASDAQ:BCDA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned approximately 0.37% of BioCardia at the end of the most recent quarter. 20.57% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BCDA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of BioCardia to a “sell” rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.